Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: A single center experience

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 835-840

  Nishikawa, Hiroki ^a   Tsudo, Mitsuru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Diffuse large B cell lymphoma; Hepatitis C virus; Hepatotoxicity; Outcome; Response; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; VIRUS LOAD;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865342817     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1883     Document Type: Article

References (30)

1. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Liso V, et al: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102: 996-999, 2003.
2. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, et al: Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116: 5119-5125, 2010.
3. De Vita S, Sacco C, Sansonno D, Gloghini A, Dammacco F, Crovatto M, Santini G, Dolcetti R, Boiocchi M, Carbone A and Zagonel V: Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 90: 776-782, 1997.
4. Pioltelli P, Zehender G, Monti G, Monteverde A and Galli M: HCV and non-Hodgkin lymphoma. Lancet 347: 624-625, 1996.
5. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K and Mueller NE: Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95: 745-752, 2004.
6. Gisbert JP, Garcia-Buey L, Pajares JM and Moreno-Otero R: Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 125: 1723-1732, 2003.
7. Izumi T, Sasaki R, Tsunoda S, Akutsu M, Okamoto H and Miura Y: B cell malignancy and hepatitis C virus infection. Leukemia 11: 516-518, 1997.
8. Galli M, Pioltelli P, Zehender G, Monti G and Monteverde A: HCV and lymphomagenesis. Lancet 348: 275, 1996.
9. Hartridge-Lambert SK, Stein EM, Markowitz AJ and Portlock CS: Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 55: 634-641, 2012.
10. Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, Ohmura H, Ikuta Y, Idobe Y and Kawasaki H: Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67: 45-50, 2001.
11. Zuckerman E, Zuckerman T, Douer D, Qian D and Levine AM: Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83: 1224-1230, 1998.
12. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, van Hoof A, Tilly H, Gaulard P, Coiffier B, et al: Groupe d'Etude des Lymphomes de l'Adulte Programs: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 24: 953-960, 2006.
13. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, et al: Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 85: 46-50, 2009.
14. Tobinai K and Hotta T: Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 34: 369-378, 2004.
15. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V and Frost SD: Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109: 845-846, 2007.
16. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M and Masauzi N: Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4: 599-608, 2005.
17. Dai MS, Chao TY, Kao WY, Shyu RY and Liu TM: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83: 769-774, 2004.
18. Niitsu N, Hagiwara Y, Tanae K, Kohri M and Takahashi N: Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 28: 5097-5100, 2010.
19. De Renzo A, Perna F, Persico M, Notaro R, Mainolfi C, de Sio I, Ciancia G, Picardi M, Del Vecchio L, Pane F and Rotoli B: Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. Eur J Haematol 81: 51-57, 2008.
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-3849, 1999.
21. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R and Lau JY: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35: 201-207, 1997.
22. Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31: 1860-1861, 1971.
23. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M and Diehl V: International Harmonization Project on Lymphoma: revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007.
24. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, Casado R, Maida I, Garcia-Gasco P and Barreiro P: Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 196: 670-676, 2007.
25. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994, 1993.
26. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, et al: Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 17: 1434-1440, 2006.
27. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Ann Intern Med 131: 174-181, 1999.
28. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D and Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357: 196-197, 2001.
29. La Mura V, De Renzo A, Perna F, D'Agostino D, Masarone M, Romano M, Bruno S, Torella R and Persico M: Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 49: 557-563, 2008.
30. Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, Picardi A, Gentilucci UV, Remotti D, et al: Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol 3: 278-284, 2011.